Evidence map›Paper›PMID 38894577›Full record

ArticleJournal of surgical oncology2024

The impact of the California state lockdown during the COVID-19 pandemic on management of patients with pancreatic ductal adenocarcinoma.

Parisa Oviedo, Shohei Burns, Wen-Pin Chen, Hanna K Mandl, Claudia Rosso, Niloofar Radgoudarzi, Anna Crosetti, Steven Zamora, Lauren M Perry, Richard J Bold and 6 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of surgical oncology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Parisa OviedoUniversity of California San Diego, Moores Cancer Center, La Jolla, California, USA.
Shohei BurnsUniversity of California  San Francisco, San Francisco, California, USA.
Wen-Pin ChenUniversity of California Irvine, Irvine, California, USA.
Hanna K MandlUniversity of California Los Angeles, Los Angeles, California, USA.
Claudia RossoUniversity of California Irvine, Irvine, California, USA.
Niloofar RadgoudarziUniversity of California San Diego, Moores Cancer Center, La Jolla, California, USA.
Anna CrosettiUniversity of California  San Francisco, San Francisco, California, USA.
Steven ZamoraUniversity of California San Diego, Moores Cancer Center, La Jolla, California, USA.
Lauren M PerryUniversity of California Davis, Davis, California, USA.
Richard J BoldMayo Clinic Comprehensive Cancer Center, Phoenix, Arizona, USA.
Amanda N LaboraUniversity of California Los Angeles, Los Angeles, California, USA.
Timothy R DonahueUniversity of California Los Angeles, Los Angeles, California, USA.
Ajay MakerUniversity of California  San Francisco, San Francisco, California, USA.
Jennifer B ValerinUniversity of California Irvine, Irvine, California, USA.
Jason A ZellUniversity of California Irvine, Irvine, California, USA.
Rebekah R WhiteUniversity of California San Diego, Moores Cancer Center, La Jolla, California, USA.ORCID http://orcid.org/0000-0003-2185-8535

Funding

UC San Diego Clinical and Translational Research InstituteUL1TR001442 · NCATS · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI FIRESTEIN, GARY S, HOGARTH, MICHAEL · 2015 to 2024
$88.3M
Univ.of Calif., Irvine Cancer Center Support GrantP30CA062203 · NCI · UNIVERSITY OF CALIFORNIA-IRVINE · PI Melanie Funes · 1994 to 2026
$57.9M
NCATS NIH HHS UL1 TR001442NCI NIH HHS P30 CA062203NIH HHS
6 · The paper itself

Abstract

BACKGROUND AND

objectivesThe SARS-COVID-19 pandemic significantly limited healthcare access. We sought to evaluate whether California's lockdown in March 2020 affected staging and time to treatment of pancreatic ductal adenocarcinoma (PDAC). We hypothesized that patients diagnosed after the lockdown would have longer time to treatment and higher stage at presentation.

methodsWe retrospectively identified and categorized 1294 patients presenting to five University of California healthcare systems with a new diagnosis of PDAC into "pre-lockdown" and "post-lockdown" groups based on timing of pathologic diagnosis.

resultsIn the 12 months pre-lockdown, 835 patients were diagnosed with PDAC, and 459 patients in the 6 months post-lockdown. Demographics, staging, and treatment type were similar between eras. There was a decreased male:female ratio post- versus pre-lockdown (0.97 vs. 1.25; p = 0.03). Time from symptom onset to first treatment was significantly increased among females post-lockdown (p = 0.001). However, overall time from diagnosis to first treatment was shorter in the post-lockdown era (median 23 vs. 26 days, p < 0.001).

conclusionsThe COVID-19 lockdown did not significantly delay initial presentation, diagnosis, or treatment of newly diagnosed PDAC patients. Time from diagnosis to first treatment was shorter post-lockdown. Reduced healthcare utilization for minor complaints and increased telehealth utilization may have contributed.

Indexed as

Carcinoma, Pancreatic DuctalCOVID-19Pancreatic NeoplasmsAdultAgedAged, 80 and overCaliforniaFemaleHumansMaleMiddle AgedNeoplasm StagingQuarantineRetrospective StudiesSARS-CoV-2Time-to-TreatmentCOVID‐19healthcare accesslockdownpancreatic cancerpandemic

Identifiers

PMID38894577
PMCPMC11323303

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.